Jatenzo After Bariatric Surgery: What Every Prescriber Needs to Know

How Jatenzo Is Absorbed and Why Bariatric Surgery Complicates That

Jatenzo bypasses hepatic first-pass metabolism by exploiting the intestinal lymphatic system. After oral ingestion with a fat-containing meal, testosterone undecanoate is incorporated into chylomicrons in enterocytes of the proximal small intestine, then transported via intestinal lymphatics into the thoracic duct and systemic circulation. [1, 2] The mechanism depends on two things that bariatric surgery can disrupt: adequate absorptive surface area in the proximal small bowel and sufficient dietary fat to trigger chylomicron assembly.

The Lymphatic Absorption Pathway

Testosterone undecanoate is a fatty-acid ester that partitions into lipid droplets during digestion. Enterocyte uptake, re-esterification into triglycerides, and packaging into nascent chylomicrons occur primarily in the duodenum and proximal jejunum. [3] This pathway is well characterized in pharmacokinetic studies of the European oral formulation (Andriol Testocaps), and the same mechanism underlies Jatenzo's FDA-approved labeling. [1]

What the Prescribing Label Says About Food

The FDA-approved prescribing information states that Jatenzo must be taken with food; administration in the fasted state reduces mean testosterone C-max by approximately 50% compared with a standardized high-fat meal. [1] A meal containing roughly 15 to 30 g of fat is considered the practical minimum to generate adequate chylomicron flux. [4]

Fat Malabsorption Risk by Procedure Type

Not all bariatric procedures affect fat absorption equally. Roux-en-Y gastric bypass (RYGB) reroutes ingested fat past the duodenum and reduces contact time with pancreatic lipase and bile salts, measurably reducing fat absorption in a subset of patients. [5] Biliopancreatic diversion with duodenal switch (BPD/DS) produces even greater fat malabsorption by design. Sleeve gastrectomy (SG) preserves normal small-bowel anatomy, so Jatenzo absorption after SG may be closer to that in non-surgical patients, though gastric-emptying changes may still alter the rate of chylomicron assembly. [6] Adjustable gastric banding (now rarely placed) does not alter intestinal anatomy and poses the least theoretical risk to lymphatic absorption.

The Hypogonadism Burden in Post-Bariatric Men

Male hypogonadism is common before and after bariatric surgery. Pre-operatively, obesity suppresses the hypothalamic-pituitary-gonadal axis through excess aromatization of androgens to estrogens in adipose tissue and through leptin/insulin resistance signaling. [7] Studies show that 40 to 64% of severely obese men meet biochemical criteria for hypogonadism (total testosterone <300 ng/dL) before surgery. [8]

Does Bariatric Surgery Restore Testosterone?

Weight loss after bariatric surgery often, but not always, normalizes testosterone. A 2012 meta-analysis by Hofstra et al. (n=373 men across 12 studies) found mean total testosterone increased from 217 ng/dL pre-operatively to 402 ng/dL post-operatively. [9] A significant minority, roughly 20 to 30%, remain hypogonadal despite substantial weight loss, either because of pre-existing primary hypogonadal disease or persistent hypothalamic suppression. [9] These men need testosterone replacement therapy (TRT), and the choice of delivery route must account for their altered anatomy.

Why Route of Administration Matters After Surgery

Injections (testosterone cypionate, testosterone enanthate, testosterone undecanoate injectable) and transdermal gels bypass gastrointestinal absorption entirely and are unaffected by bariatric anatomy. [10] Nasal and buccal formulations also bypass the GI tract. Oral testosterone undecanoate (Jatenzo) is the only FDA-approved oral option but carries unique post-bariatric risk because its absorption depends on an intact proximal small bowel. [1] Clinicians choosing Jatenzo for post-bariatric patients are trading injection avoidance for a monitoring obligation that does not exist for transdermal or injectable routes.

Jatenzo's Key Trial Data: The Swerdloff 2020 Study

The cornerstone efficacy and safety dataset for Jatenzo comes from Swerdloff et al., published in the Journal of Clinical Endocrinology and Metabolism in 2020. [11] The open-label Phase 3 trial enrolled 166 hypogonadal men (baseline total T <300 ng/dL). After dose titration, 87% of subjects achieved average serum testosterone concentrations within the normal range (300 to 1,050 ng/dL) at the 3-month assessment. Mean C-avg was 498 ng/dL (range 329 to 737 ng/dL across the 8-hour pharmacokinetic window). [11]

Key PK Parameters from Swerdloff et al.

• T-max occurred at approximately 2 to 4 hours post-dose.
• The mean C-max was 1,176 ng/dL under fed conditions.
• Dose distribution after titration: 37% remained at 237 mg twice daily, 29% required 158 mg twice daily (downward titration), and 34% required 396 mg twice daily (upward titration). [11]

Notably, the trial excluded patients with any gastrointestinal disease affecting absorption, which means the post-bariatric population was not studied and all post-bariatric prescribing is off-protocol relative to the key dataset. [11]

Blood Pressure Signal

Swerdloff et al. Documented a mean systolic blood pressure increase of 3 to 5 mmHg in subjects on Jatenzo. [11] The FDA subsequently required a cardiovascular warning in the label. [1] Post-bariatric patients frequently have comorbid hypertension, making this signal clinically meaningful; blood pressure should be confirmed within 6 weeks of initiating or uptitrating Jatenzo in this population.

Pharmacokinetics in Malabsorptive States: What the Literature Shows

No randomized controlled trial has specifically studied Jatenzo pharmacokinetics in post-bariatric patients. The evidence base draws from related oral lipophilic drugs and from published case reports and pharmacokinetic modeling.

Evidence from Andriol Testocaps (European Oral TU)

Andriol Testocaps (testosterone undecanoate 40 mg in oleic acid), the predecessor formulation available outside the United States, provides the closest analog data. A case series published by Comninos et al. In Clinical Endocrinology (2019) described three RYGB patients who had subtherapeutic testosterone levels on Andriol Testocaps despite escalating doses; switching to transdermal testosterone normalized levels in all three. [12] These findings suggest that RYGB may substantially impair lymphatic absorption of oral testosterone undecanoate, though no bioequivalence study between Andriol Testocaps and Jatenzo in this population exists.

Oral Drug Absorption After RYGB: Broader Evidence

A 2014 systematic review by Lam et al. In Obesity Surgery examined 25 drugs with altered pharmacokinetics after RYGB. [13] Drugs that undergo lymphatic absorption showed the most variable post-operative profiles. Mean absorption of lipophilic compounds decreased by 20 to 60% in RYGB patients compared with matched controls, depending on meal fat content and time since surgery. [13] Applying this range to Jatenzo's standard 237 mg twice-daily dose suggests that effective absorbed testosterone undecanoate could fall to a level equivalent to 95 to 190 mg twice daily, which may be insufficient for many patients. [1]

Sleeve Gastrectomy: A More Favorable Profile

Sleeve gastrectomy preserves duodenal and jejunal anatomy. A pharmacokinetic analysis of cyclosporine (another lymphatically absorbed lipophilic drug) after sleeve gastrectomy found no statistically significant reduction in AUC compared with non-surgical controls. [14] While cyclosporine is not testosterone undecanoate, both undergo chylomicron-mediated lymphatic transport, and the data suggest sleeve gastrectomy poses a lower malabsorption risk. Clinicians may reasonably expect more predictable Jatenzo exposure in sleeve patients, though prospective data are still lacking. [14]

Dosing and Titration Protocol for Post-Bariatric Patients

The FDA-approved starting dose is 237 mg (two 158 mg capsules) twice daily with food, with titration based on a serum total testosterone drawn 3 to 5 hours after the morning dose at week 3 to 4 of therapy. [1] For post-bariatric patients, the HealthRX clinical team recommends a modified monitoring schedule given the unpredictability of absorption.

Recommended Monitoring Framework for Post-Bariatric Men on Jatenzo

Baseline (before starting Jatenzo):

• Serum total testosterone (morning, 8 to 10 AM)
• Sex hormone-binding globulin (SHBG) and calculated free testosterone
• Hematocrit and hemoglobin
• PSA (age-appropriate, per AUA/Endocrine Society guidance) [15]
• Fasting lipid panel
• Blood pressure

Week 3 to 4 post-initiation:

• Serum total testosterone drawn 3 to 4 hours after the morning dose with a standardized meal (record fat content)
• Blood pressure check
• Symptom review (energy, libido, erythrocytosis symptoms)

Titration rules (adapted from FDA label for post-bariatric context):

• If total T is <300 ng/dL at 3 to 4 hours: increase dose by one capsule per administration (e.g., 237 mg to 316 mg or 316 mg to 396 mg twice daily). [1]
• If total T exceeds 1,050 ng/dL: decrease dose by one capsule per administration.
• If the patient is already at maximum 396 mg twice daily with persistent sub-therapeutic levels: consider switching to a non-oral formulation. [1]

Every 3 months for the first year:

• Serum total testosterone (3 to 4 hours post-dose)
• Hematocrit (hold or reduce dose if hematocrit exceeds 54%) [15]
• Blood pressure

Annually thereafter (if stable):

• Full lab panel as above plus PSA, metabolic panel

Fat Content Standardization

Post-bariatric patients often eat smaller meals. To ensure adequate chylomicron assembly, advise patients to take each Jatenzo dose with a meal or snack that includes at least 15 g of fat, such as two tablespoons of peanut butter, one avocado half, or a full-fat Greek yogurt. Patients who have undergone RYGB should be counseled that even with a fat-containing meal, absorption may be reduced. [5]

Safety Considerations Specific to Post-Bariatric Patients

Polycythemia Risk

Testosterone increases erythropoietin production, raising hematocrit. In the Swerdloff trial, hematocrit exceeded 54% in 8 of 166 subjects (4.8%) during the study period. [11] Post-bariatric patients may already have elevated hematocrit from dehydration or supplemental iron therapy for post-surgical iron-deficiency anemia; the two effects can combine. Baseline and quarterly hematocrit monitoring is mandatory, and dose reduction or temporary suspension is indicated if hematocrit reaches 54%. [1]

Cardiovascular Risk

The Endocrine Society's 2018 Clinical Practice Guideline on testosterone therapy states: "We recommend against initiating testosterone therapy in patients with a recent major adverse cardiovascular event (MACE) within the preceding 6 months." [15] Post-bariatric patients who experienced cardiovascular events perioperatively or who have active heart failure should be evaluated carefully before Jatenzo initiation. The mean 3 to 5 mmHg systolic blood pressure increase seen in Swerdloff et al. [11] may push borderline-controlled hypertension into uncontrolled territory.

Drug-Drug Interactions in Post-Bariatric Patients

Many post-bariatric patients take medications that interact with testosterone or that have their own altered pharmacokinetics. Testosterone may potentiate warfarin (monitor INR), interact with insulin (monitor glucose), and increase cyclosporine levels. [1] Because RYGB also alters oral drug absorption broadly, a medication reconciliation review is advisable at each Jatenzo titration visit. [13]

Nutritional Deficiencies and Androgen Metabolism

Post-bariatric patients are at risk for zinc and vitamin D deficiency, both of which affect testosterone biosynthesis and SHBG levels. [16] Low zinc has been associated with reduced testicular testosterone production in small studies, and vitamin D deficiency correlates inversely with serum testosterone in population data from NHANES (N=3,369). [17] Correcting these deficiencies before or alongside TRT initiation may improve endogenous testosterone production in men with partial rather than complete gonadal failure. Nutritional status should be assessed before ascribing persistent hypogonadism entirely to absorption failure of Jatenzo. [16]

When to Switch Away from Jatenzo Post-Bariatric

Several clinical signals should prompt switching from Jatenzo to a non-oral testosterone formulation.

Clinical Criteria for Switching

A patient should be considered for formulation change if:

1. Serum total T at 3 to 4 hours post-dose remains <300 ng/dL at maximum dose (396 mg twice daily) after two consecutive titration intervals. [1]
2. The patient cannot reliably eat a fat-containing meal with each dose (common after RYGB due to dumping syndrome or early satiety).
3. The patient develops uncontrolled hypertension on Jatenzo that does not resolve with antihypertensive adjustment.
4. There is persistent symptomatic hypogonadism (fatigue, low libido, loss of lean mass) despite serum T in the nominal normal range, suggesting the post-dose peak-trough variability inherent in twice-daily oral dosing is not maintaining adequate average exposure.

Alternative Formulations to Consider

Testosterone cypionate 100 to 200 mg IM or subcutaneously every 1 to 2 weeks provides steady, anatomy-independent delivery. [10] Testosterone undecanoate injectable (Aveed, 750 mg IM at weeks 0, 4, then every 10 weeks) offers the least frequent injection schedule. [18] Transdermal testosterone gel 1.62% (AndroGel) or 2% (Fortesta) avoids injections and GI absorption entirely; testosterone C-avg in the Testim gel key trial (N=406) reached 588 ng/dL at 90 days with the 10 g dose. [19]

Practical Prescribing Checklist for Post-Bariatric Jatenzo

Below is a condensed reference for clinicians at the point of prescribing.

| Step | Action | Timing | |------|--------|--------| | 1 | Confirm hypogonadism: two morning total T <300 ng/dL plus symptoms | Before prescribing | | 2 | Identify bariatric procedure type (RYGB, SG, BPD/DS, band) | Before prescribing | | 3 | Counsel on fat-meal requirement; assess meal tolerance post-surgery | Before prescribing | | 4 | Start 237 mg twice daily with food | Day 1 | | 5 | Draw total T 3 to 4 hours post-dose + BP check | Week 3 to 4 | | 6 | Titrate by one capsule per dose interval based on level | Week 3 to 4 or 6 | | 7 | Check hematocrit, BP, T level | Month 3, 6, 9, 12 | | 8 | Switch formulation if max dose fails or meal tolerance insufficient | As needed |

Clinical Guidance from Current Guidelines

The Endocrine Society 2018 guideline specifies that TRT is indicated when "there are signs and symptoms of testosterone deficiency and consistently low morning serum testosterone concentrations on at least two occasions." [15] The guideline does not address post-bariatric patients specifically, leaving the choice of formulation to clinical judgment. The American Association of Clinical Endocrinology (AACE) 2022 position statement on male hypogonadism similarly omits bariatric-specific dosing guidance, though it recommends confirming adequate absorption for any oral medication in patients with malabsorptive procedures. [20]

"Clinicians should use the lowest effective testosterone dose and the formulation best suited to the patient's anatomy, lifestyle, and comorbidities," states the Endocrine Society guideline. [15] For post-bariatric patients on Jatenzo, that principle translates directly into the frequent monitoring schedule and low threshold for formulation switching described in this article.